

HOW TO CLAIM CREDIT

Please scan QR code or visit <https://www.chicagolympoma.com/IUCLS2024> to complete the program evaluation and receive continuing education credit for your participation.



Accreditation and Certification

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Chicago Pritzker School of Medicine and Bio Accord LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™ for physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

University of Chicago Medicine is accredited as a provider of continuing nursing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Participants who successfully complete the entire activity and complete an evaluation form will earn 13.75 contact hours.

American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other Participant Credit

Other participants will receive a Certificate of Participation for information on the applicability and assessment of this activity for your own accreditation purposes. For AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.

Dear Friends and Colleagues,

Welcome to Chicago and to the 21st International Ultramann Chicago Lymphoma Symposium (IUCLS)! This annual conference is dedicated solely to the science and clinical care of lymphoma and is the only lymphoma-specific symposium in the Midwest. It was originally organized to honor the achievements of Dr. John Ultramann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. We are thrilled to have a multitude of the world's experts in lymphoma speak at IUCLS. Furthermore, we are proud to leverage the lymphoma expertise and interaction of the 5 academic centers throughout the Chicago community.

There continues to be increasing developments in the epidemiology, biology, and diagnosis of Hodgkin and non-Hodgkin lymphoma with multiple therapeutic breakthroughs. This includes improved understanding and application of molecular medicine and genomics to the diagnosis and treatment of lymphoma, the development of novel immunotherapies, several new FDA-approved targeted therapies, the development of novel monoclonal antibodies, antibody-drug conjugates, and CAR-T cell treatment and other immunotherapies. Additionally, the role of survivorship for lymphoma patients continues to be implemented into clinical practices as our patients live longer.

It is important for clinicians to stay up-to-date on the changing therapeutic landscape to achieve optimal patient outcomes. Additionally, this meeting is designed to facilitate an informal exchange of ideas and questions among all participants, and we highly encourage you to ask questions and provide comments and feedback throughout the meeting. We are happy to highlight the collaboration and interaction among medical oncologists/hematologists, radiation oncologists, pathologists, fellows-in-training, oncology nurses, advanced practitioners, pharmacists, and allied health professionals committed to the diagnosis and treatment of lymphoma.

Thank you very much for your time and contribution. We are excited to welcome you to Chicago!

#IUCLS2024 CO-CHAIRS



**Sonali M. Smith,
MD, FASCO**

Elwood V Jensen Professor of Medicine, Chief, Section of Hematology, and Director, Lymphoma Program, The University of Chicago
Chicago, Illinois



**Andrew Events,
DO, MBA, MSC**

Associate Vice Chancellor, Clinical Innovation & Data Analytics, Rutgers Biomedical and Health Sciences, Medical Oncology and Hematology, Rutgers Cancer Institute of New Jersey, Director, Oncology Lead for RWJ Barnabas Health
New Brunswick, New Jersey



**Timothy Fenske,
MD, MS**

Professor, Division of Hematology and Oncology, Medical Oncology
Madison, Wisconsin



**Neha Mehta-Shah,
MD, MSCI**

Associate Professor, Washington University School of Medicine, Division of Hematology and Oncology
St. Louis, Missouri

21ST INTERNATIONAL ULTMANN CHICAGO LYMPHOMA SYMPOSIUM™

APRIL 19-20, 2024

21ST INTERNATIONAL ULTMANN CHICAGO LYMPHOMA SYMPOSIUM

A 2-day, thought-provoking symposium featuring the leading experts dedicated to the science and clinical care of lymphoma.

THIS ACTIVITY IS JOINTLY PROVIDED BY



CHICAGOLYMPOMA.COM

Share your experiences with us on social media using #IUCLS2024



#IUCLS2024 ADVISORY COMMITTEE MEMBERS



Reem Karmali, MD
The University of Chicago
Chicago, IL



Kalkin Kelly, PharmD, BCOP
The University of Chicago
Chicago, IL



Tara McCabe, APN-BC, AOCNP
The University of Chicago
Chicago, IL



Neha Mehta-Shah, MD, MSCI
The University of Chicago
Chicago, IL



Grace Rivers, MSN, ACPNP-BC
The University of Chicago
Chicago, IL



Kalkin Kelly, PharmD, BCOP
The University of Chicago
Chicago, IL



Paul Rubinstein, MD
The University of Chicago
Chicago, IL



Justin Kline, MD
The University of Chicago
Chicago, IL



Timothy Fenske, MD, MS
The University of Chicago
Chicago, IL



Gireh Venkataraman, MD
The University of Chicago
Chicago, IL



Reem Karmali, MD
The University of Chicago
Chicago, IL



Jennifer Crombie, MD
The University of Chicago
Chicago, IL

FRIDAY, APRIL 19, 2024

| Time (GST) | Interprofessional Session | Presenter |
|--------------------|--|--|
| 7:00 - 8:00 AM | Registration, Breakfast & Exhibits | |
| 8:00 - 8:15 AM | Welcome, Introductions and Pre-session ARS | |
| 8:15 - 9:25 AM | Mini Symposium on Bispecifics | Moderator: Kirk Cahill, MD |
| 8:15 - 8:45 AM | Overview of Bispecific Antibodies: Comparing and Contrasting Current and Emerging Agents | Tara McCabe, APN-BC, AOCNP |
| 8:45 - 9:15 AM | Practical Aspects of Bispecifics: Supportive Care Strategies | Kalkin Kelly, PharmD, BCOP |
| 9:15 - 9:25 AM | Panel Discussion, Q&A, and Post-session ARS | |
| 9:25 - 9:45 AM | Summary: Our Patients with All-Recycling Immunotherapeutic Differentiating Checkpoint Inhibitors vs Antibody-Drug Conjugates | Rebecca Follenweider, BSN, RN, OCN |
| 9:45 - 9:55 AM | Panel Discussion with Cases | Rebecca Follenweider, BSN, RN, OCN, Kalkin Kelly, PharmD, BCOP, Grace Rivers, MSN, ACPNP-BC |
| 9:55 - 10:15 AM | Break & Exhibits | |
| 10:15 - 11:30 AM | Mini Symposium on Advanced Technology in Cancer Care | Moderator: Neha Mehta-Shah, MD, MSCI |
| 10:15 - 10:20 AM | Pre-session ARS | |
| 10:20 - 10:50 AM | Artificial Intelligence and Computational Oncology | Frederick Howard, MD |
| 10:50 - 11:20 AM | Primer on CRISPR and Its Impact on Cancer Research and Treatment | Justin Kline, MD |
| 11:20 - 11:30 AM | Panel Discussion, Q&A, and Post-session ARS | |
| 11:30 AM - 1:00 PM | Lunch & Exhibits | |
| 1:00 - 1:10 PM | General Session | Presenter |
| 1:00 - 1:05 PM | Welcome and Introductions | Sonal Smith, MD, FASCO |
| 1:05 - 2:30 PM | Mini Symposium on T-cell Lymphoma | Moderator: Sonali Smith, MD, FASCO |
| 1:05 - 1:10 PM | Pre-session ARS | |
| 1:10 - 1:30 PM | Epigenetics in T-cell Lymphoma: Has the Promise Been Fulfilled? | Ericca Marchi, MD |
| 1:30 - 1:50 PM | Novel Therapeutics for T-cell Lymphoma and Lessons Learned from the Current Regulatory Environment | Swananthan Iyer, MD |
| 1:50 - 2:10 PM | Management of Advanced CTCL | Neha Mehta-Shah, MD, MSCI |
| 2:10 - 2:30 PM | Panel Discussion, Q&A, and Post-session ARS | |
| 2:30 - 2:50 PM | Break & Exhibits | |
| 2:50 - 3:50 PM | Hematopathology Tumor Board Discussion | Moderator: Andrew Evans, DO, MBA, MSc; Gireh Venkataraman, MD, Kirk Cahill, MD, Anamajaya Perry, MD |
| 3:50 PM | Panel Discussion and Q&A | Moderator: Reem Karmali, MD |
| 4:00 - 5:20 PM | Pre-session ARS | |
| 4:00 - 4:05 PM | Bispecifics for LBCL: Focus on Management of Toxicities in the Community | Jennifer Crombie, MD |
| 4:05 - 4:25 PM | Bispecifics for FL | David Russler-Germain, MD, PhD |
| 4:25 - 4:45 PM | Sequencing of Bispecifics with Other Therapies | Elizabeth Bucde, MD, PhD |
| 4:45 - 5:05 PM | Panel Discussion, Q&A, and Post-session ARS | |
| 5:05 - 5:20 PM | Day 1 Wrap Up and Summary | Moderator: Timothy Fenske, MD, MS |
| 5:20 PM | Welcome & Poster Reception with Exhibitors | |
| 5:30 - 6:30 PM | | |

SATURDAY, APRIL 20, 2024

| Time (GST) | General Session | Presenter |
|---------------------|--|--|
| 7:00 - 8:00 AM | Registration, Breakfast & Exhibits | |
| 8:00 - 8:05 AM | Welcome and Introductions | Neha Mehta-Shah, MD, MSCI |
| 8:05 - 8:25 AM | DEI Keynote Presentation | Moderator: Ruema Bhirray, MD |
| 8:25 - 8:30 AM | Implementation of Reducing Barriers to Accessing Lymphoma Care | Christopher R. Flowers, MD, MS |
| 8:30 - 8:35 AM | Q&A | |
| 8:30 - 10:10 AM | Mini Symposium on Hodgkin Lymphoma | Moderator: Andrew Evans, DO, MBA, MSc |
| 8:30 - 8:35 AM | Pre-session ARS | |
| 8:35 - 8:55 AM | Ensuring the Progress in Hodgkin Lymphoma Applies to All Patients | Justin Kline, MD |
| 8:55 - 9:15 AM | Are Checkpoint Inhibitors the Standard of Care for Frontline Hodgkin Lymphoma? | Boyu Hu, MD |
| 9:15 - 9:35 AM | What is the Standard of Care in Second-Line Hodgkin Lymphoma? | Sarah Rutherford, MD |
| 9:35 - 9:55 AM | Who Benefits the Most from Radiation in Hodgkin Lymphoma? | Chelsea C. Pinnix, MD, PhD |
| 9:55 - 10:10 AM | Panel Discussion, Q&A, and Post-session ARS | |
| 10:10 - 10:30 AM | Break and Exhibits | |
| 10:30 AM - 12:10 PM | Our Symposium: Measuring WPD Is the Standard of Care in CLL | Moderators: Timothy Fenske, MD, MS & Leo Gordon, MD |
| 10:30 - 10:35 AM | Pre-session ARS | |
| 10:35 AM | Yes | Joanna Rhodes, MD, MSCE |
| 10:55 AM | No | Jacob Soumerai, MD |
| 11:05 AM | AYA Patients | Ami LaCarico, MD, MMSc |
| 11:35 AM | Elderly/Older Patients | Sterfano Luminari, MD |
| 11:55 AM - 12:10 PM | Panel Discussion, Q&A, and Post-session ARS | |
| 12:10 - 1:25 PM | Lunch, Exhibits, & Meet the Professor Session | |
| 1:25 - 2:25 PM | Keynote Presentation | Moderator: Sonali Smith, MD, FASCO |
| 2:25 - 2:30 PM | Can We Accelerate Progress in Lymphoma? | Andrew Zelenetz, MD, PhD |
| 2:30 - 2:35 PM | Pre-session ARS | |
| 2:35 - 2:50 PM | Targeting BTK Inhibitors vs Degraders | Adam Kitai, MD |
| 2:50 - 3:10 PM | PI3K: Is Targeting This Pathway Still Valuable? | Changchun Deng, MD, PhD |
| 3:10 - 3:30 PM | The Next Frontier of Targeted Therapy in Lymphoma | Kam J. Madlocks, MD |
| 3:30 - 3:45 PM | Panel Discussion Q&A, and Post-session ARS | |
| 3:45 - 3:55 PM | Summary and Best of IUCLS | Moderator: Timothy Fenske, MD, MS |
| 3:55 PM | Adjourn | |